May 23, 2024Open Access

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

CT-P13 subcutaneous (SC), an SC formulation of the intravenous (IV) infliximab biosimilar CT-P13 IV, creates a unique exposure profile. The LIBERTY studies aimed to demonstrate superiority of CT-P13 SC vs placebo as maintenance therapy in patients with Crohn's disease (CD) and ulcerative colitis (UC).

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Hanauer et al. (Thu,) studied this question.

synapsesocial.com/papers/68e68ab2b6db643587612844 https://doi.org/https://doi.org/10.1053/j.gastro.2024.05.006

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1World Medical Association Declaration of Helsinki2013 · 29,402 citations
2Unravelling the pathogenesis of inflammatory bowel disease2007 · 4,335 citations
3Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit2022 · 23 citations
4Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era2022 · 28 citations
5CT-P13: design, development, and place in therapy2017 · 28 citations

Me gusta

Guardar

Ver artículo completo